Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement, to Pursue Independent Paths

Onconetix and Ocuvex have mutually terminated their merger agreement, citing that pursuing independent paths is in the best interest of their stakeholders. Ocuvex will proceed with the commercial launch of Omlonti and continue advancing its pipeline, while Onconetix will focus on delivering innovative solutions for men's health and oncology. Both companies express appreciation for the collaborative spirit shown during the merger discussions.

Onconetix Inc. (ONCO) and Ocuvex Therapeutics Inc. have mutually terminated their merger agreement, effective September 26, 2025 Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement^[1]. The decision, following careful consideration and constructive dialogue, reflects the strong commitment of both companies to advancing their respective missions and delivering value to stakeholders.

The termination does not impact Ocuvex’s momentum or its commitment to patients. The company has recently obtained its New Jersey state pharmaceutical license and is set to launch Omlonti in the coming weeks. Ocuvex’s pipeline continues to advance, and the company remains focused on delivering innovative ophthalmic solutions to the market Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement^[1].

Onconetix, a commercial-stage biotechnology company focused on men's health and oncology, will continue to focus on delivering innovative solutions in these areas. The company's key products include Proclarix®, an in vitro diagnostic test for prostate cancer, and ENTADFI, an FDA-approved daily treatment combining finasteride and tadalafil for benign prostatic hyperplasia Onconetix Stock Price, News & Analysis^[2].

Both companies have expressed appreciation for the collaborative spirit shown throughout the merger discussions. They look forward to future collaborations and maintaining a positive relationship despite the termination of the merger agreement.